Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Buparlisib + Letrozole in HR+/HER2- Advanced Breast Cancer
NCT02154776Phase 1Completed
- Sponsor
- Novartis
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ribociclib and buparlisib in breast cancer, sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Safety and tolerability at 25 months. Started Jun 2014; status: completed.
02
Drugs
ribociclibbuparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02154776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154776.